ReviewRevista do Instituto de Medicina Tropical de Sao Paulo2015
PARACOCCIDIOIDOMYCOSIS TREATMENT.
Review in Revista do Instituto de Medicina Tropical de Sao Paulo, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 83 citations in OpenAlex.
- Synergistic Effect of 5-Fluorouracil and Amphotericin B in Murine Paracoccidioidomycosis: Immune Modulation and Enhanced Fungal Clearance.ACS infectious diseases · 2026Article
- Combined anti-PD-1 and amphotericin B therapy reduces fungal burden and enhances control of murine paracoccidioidomycosis.Frontiers in cellular and infection microbiology · 2026Article
- Low-level LASER therapy accelerates fungal lesions cicatrization by increasing the production of Th1 and Th2 cytokines.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Blocking the CTLA-4 and PD-1 pathways during pulmonary paracoccidioidomycosis improves immunity, reduces disease severity, and increases the survival of infected mice.Frontiers in immunology · 2024Article
- Make the diagnosis - Second partBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Proteomic Profiling ofJournal of fungi (Basel, Switzerland) · 2023Article
- Clinical Manifestations of Human Exposure to Fungi.Journal of fungi (Basel, Switzerland) · 2023Review
- Factors influencing treatment adherence in paracoccidioidomycosis in Brazil.Public health challenges · 2023Article
- Proteomic Response ofJournal of fungi (Basel, Switzerland) · 2022Article
- Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment.Journal of fungi (Basel, Switzerland) · 2022Review
- In vitro and in silico analysis reveals antifungal activity and potential targets of curcumin on Paracoccidioides spp.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021Review
- Antibody- Based Immunotherapy Combined With Antimycotic Drug TMP- SMX to Treat Infection WithFrontiers in immunology · 2021Article
- Article
- Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Oral paracoccidioidomycosis in a non-endemic region from Brazil: A short case series.Journal of clinical and experimental dentistry · 2019Article
- Antifungal activity of two oxadiazole compounds for the paracoccidioidomycosis treatment.PLoS neglected tropical diseases · 2019Article
- The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease.PLoS neglected tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considered to be an emerging endemic mycosis in Latin America, paracoccidioidomycosis is characterized by a chronic course and involvement of multiple organs in immunocompromised hosts. Infection sequelae are mainly related to pulmonary and adrenal insufficiency. The host-parasite interaction results in different expressions of the immune response depending on parasite pathogenicity, fungal load and genetic characteristics of the host. A few controlled and case series reports have shown that azoles and fast-acting sulfa derivatives are useful treatment alternatives in milder forms of the disease. For moderate/severe cases, more prolonged treatments or even parenteral routes are required especially when there is involvement of the digestive tract mucosa, resulting in poor drug absorption. Although comparative studies have reported that shorter treatment regimens with itraconazole are able to induce cure in chronically-infected patients, there are still treatment challenges such as the need for more controlled studies involving acute cases, the search for new drugs and combinations, and the search for compounds capable of modulating the immune response in severe cases as well as the paradoxical reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.